Vensica Medical – a pioneering urology therapeutics company, announced the closing of an $11 million funding round. This funding was led by Israel Biotech Fund (IBF), along with key strategic partners Merz (a global player in neurotoxins) and Laborie (a prominent urology medical device company). This funding round will enable Vensica to continue its mission of providing a minimally invasive, simple, and effective solution for people with overactive bladder (OAB).
The funding will advance the company’s upcoming Phase 2 clinical trials across the US and Europe for its transformative treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin) delivered through a proprietary needle-free device.
Vensica’s unique technology utilizes a needle-free drug delivery system, that administers Xeomin directly to the bladder wall. And this approach is expected to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica’s needle-free drug delivery system aims to be a urology treatment platform for the treatment of additional bladder indications.
As part of a strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin in needle-less therapeutic application in several urologic indications and will benefit from Merz’s clinical development support. And this collaboration marks a significant step forward in the company’s goal of delivering next-generation urology treatments.
KEY QUOTES:
“We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment. This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it.”
– Avner Geva, CEO of Vensica
